INYX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0001 USD | +9,900.00% |
|
0.00% | +9,900.00% |
| Sales 2004 | 15.7M 1.31B | Sales 2005 | 49.56M 4.13B | Capitalization | 75.26M 6.28B |
|---|---|---|---|---|---|
| Net income 2004 | -16M -1.33B | Net income 2005 | -31M -2.58B | EV / Sales 2004 | 3.37 x |
| Net Debt 2004 | 14.45 1.2K | Net Debt 2005 | 98.53 8.21K | EV / Sales 2005 | 1.52 x |
| P/E ratio 2004 |
-2.67
x | P/E ratio 2005 |
-2.41
x | Employees | 572 |
| Yield 2004 * |
-
| Yield 2005 |
-
| Free-Float | 98.86% |
More Fundamentals
* Assessed data
| 1 day | +9,900.00% |
1 month
0.00
0.00
Current year
0.000.00
1 year
0.000.00
3 years
0.000.00
5 years
0.000.01
10 years
0.000.20
Inyx, Inc. is a provider of specialty pharmaceutical products and technologies. Its operations are focused on the development of both prescriptions, over the counter pharmaceutical products, and specialty consulting services. Also, the Company utilizes niche drug delivery capabilities to develop its own products. The product and service categories of the Company include Metered Dose Inhalers (MDIs) (CFC & HFA), Dry Powder Inhalers (DPIs), Metered Dose Pump Sprays (nasal and oral), Hydrocarbon Foam Aerosols, Saline Aerosols, Sterile Solutions/Injectables, Solid Dose, Formulation Services, Analytical Development Validation, Stability Services, Regulatory Support and Integrated Project Management.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +9,900.00% | 5.31K | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- IYXI Stock
